Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:57:52.627Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:57:52.627Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9e30a8d320e3cb26c3b838953cbb8bfe3908fe2cbbcdc0c218fd5db8a33f332
FORWARD PE RATIO
N/A
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.05M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.05M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
Consensus estimates for this stock are reported in ILS, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
